First of new generation of cancer drugs granted European approval
A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has today become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. ...
Dec 18, 2014
0
0